Research into treatment for cardiovascular prevention in patients with SLE is still under study, evaluating drugs with different mechanisms of action, such as belimumab, mechanistic target of rapamycin (mTOR) inhibitors, and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors [11]. Here, PCSK9 is linked to systemic lupus erythematosus.